The hormone therapy drug abiraterone (Zytiga) can significantly extend the lives of prostate cancer patients by slowing tumor progression and increasing survival rates. These findings came from two clinical trials presented this weekend at the 2017 ASCO Annual Meeting.
Hormone Therapy Drug Shows Promise In Upping Survival Rates Of Prostate Cancer Patients
Tech Times - 7 Jun 2017 19:08
The hormone therapy drug abiraterone (Zytiga) can significantly extend the lives of prostate cancer patients by slowing tumor progression and increasing survival rates. These findings came from two clinical trials presented this weekend at the 2017 ASCO Annual Meeting.
Share this Article
Recommended